Drug profile · INN
gadofosveset trisodium
ABLAVAR (PREVIOUSLY VASOVIST)
gadofosveset trisodium (ABLAVAR (PREVIOUSLY VASOVIST)) is a diagnostic agent. Route of administration: intravenous. Current US regulatory status: approved.
Drug details — gadofosveset trisodium
- US status
- approved
- Class
- Various (V08)
- Route
- INTRAVENOUS
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
gadofosveset trisodium (ABLAVAR (PREVIOUSLY VASOVIST)) is a diagnostic agent. Route of administration: intravenous. Current US regulatory status: approved.
Key facts
Mechanism of action
Diagnostic agent
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | withdrawn | — |
Related & competitor drugs
Frequently asked questions
What is gadofosveset trisodium?
gadofosveset trisodium (ABLAVAR (PREVIOUSLY VASOVIST)) is a diagnostic agent. Route of administration: intravenous. Current US regulatory status: approved.
What is the brand name for gadofosveset trisodium?
ABLAVAR (PREVIOUSLY VASOVIST) is a marketed brand name for gadofosveset trisodium. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of gadofosveset trisodium?
gadofosveset trisodium has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.